Livforsakringsbolaget Skandia Omsesidigt Acquires 600 Shares of McKesson Corporation $MCK

Livforsakringsbolaget Skandia Omsesidigt raised its holdings in McKesson Corporation (NYSE:MCK) by 2.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,032 shares of the company’s stock after buying an additional 600 shares during the quarter. McKesson accounts for 0.9% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 18th largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in McKesson were worth $20,883,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of MCK. J.W. Cole Advisors Inc. increased its holdings in shares of McKesson by 35.3% during the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares in the last quarter. Private Wealth Partners LLC lifted its holdings in shares of McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after purchasing an additional 1,682 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares in the last quarter. CW Advisors LLC grew its position in McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after purchasing an additional 8,130 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in McKesson by 12.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after purchasing an additional 36,451 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity

In other news, EVP Michele Lau sold 2,725 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the transaction, the executive vice president owned 3,247 shares in the company, valued at $3,214,530. The trade was a 45.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,868 shares of company stock worth $3,743,820. Corporate insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

MCK has been the topic of several research reports. Barclays upped their price objective on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday. Mizuho upped their target price on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. Evercore reaffirmed an “outperform” rating on shares of McKesson in a research report on Thursday, March 5th. Finally, Wells Fargo & Company lifted their price target on McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $960.93.

McKesson Trading Down 0.1%

Shares of NYSE:MCK opened at $942.57 on Wednesday. The stock has a market cap of $115.45 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 1.52 and a beta of 0.38. The stock’s fifty day simple moving average is $898.61 and its two-hundred day simple moving average is $830.00. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter in the prior year, the business posted $8.03 EPS. The business’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.